Institute of Cancer Research

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024

Retrieved on: 
Wednesday, April 10, 2024
PSMA, Institute of Cancer Research, Cancer, MSLN, Clinical Cancer Research, Cancer research, Research, The Institute, Half-life, PD-L1, Prostate cancer, CD137, VH, Therapy, Patient, APC, Toxicity, AACR, Antibody, Annual general meeting, Dynamics (music), Pharmacology, NK

Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.

Key Points: 
  • Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.
  • The data from our two lead programmes highlight the potential of immuno-oncology therapies that are potent and long-lasting, yet well-tolerated by patients.
  • “The pharmacology data we have shared on CB307, underpins its clinical development in PSMA+ metastatic castration-resistant prostate cancer (mCRPC), which continues at pace in our ongoing Phase 1b trial.
  • The details of this research have also been published in Clinical Cancer Research, a journal of the AACR.

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

Retrieved on: 
Friday, April 5, 2024
TME, Development, FAP, Doctor of Philosophy, Patient, Doxorubicin, Tumor microenvironment, Royal Marsden Hospital, MD, AACR, Research and development, Institute of Cancer Research, Poster, Heterotrimeric G protein, BST, AIM, Fine chemical

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

Key Points: 
  • Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
  • A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/ .
  • Christina Coughlin will provide a video presentation overview examining the data presented in the poster.
  • Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data.

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2023 CHALLENGE AWARDS TOTALING MORE THAN $21 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Thursday, March 14, 2024
University of Illinois Urbana-Champaign, PCF, University of Sydney, Prostate cancer, Genetic testing, Immunotherapy, Prostate Cancer Foundation, Lund University, Oncogene, Patient, PET, Biomarker, Research, Aircraft pilot, University, Doctor of Philosophy, Biology, MBA, MPH, Johns Hopkins University, Institute of Cancer Research, CBP, University of Pretoria, PSMA, Medical imaging

LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.
  • PCF Challenge Awards fund international, multi-institutional, cross-disciplinary teams of investigators conducting highly innovative research with the greatest potential for accelerating new and improved treatments for advanced prostate cancer.
  • Following a rigorous peer review process that assessed each project's scientific merit and potential patient impact, 20 highly coveted PCF Challenge Awards totaling $21.3 million were granted to teams at some of the world's leading cancer research institutions.
  • (Evaluating the impact of treatment with darolutamide on age-related outcomes in vulnerable, older patients with metastatic hormone-sensitive prostate cancer.)

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Retrieved on: 
Tuesday, March 5, 2024
Institute of Cancer Research, FAP, Royal Marsden Hospital, Doctor of Philosophy, Heterotrimeric G protein, MD, TME, AACR, AIM, Tumor microenvironment, Patient, Poster, Fine chemical

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Key Points: 
  • Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
    Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
  • The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below.
  • Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust
    For further information from Avacta Group plc, please contact:

The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch

Retrieved on: 
Thursday, February 8, 2024
RaySearch Laboratories, Research, Patient, Radiation, Institute of Cancer Research, Physics, Disease, Royal Marsden Hospital, Anatomy, Hospital

Thanks to funding from The Royal Marsden Cancer Charity, the center recently acquired two additional Radixact treatment delivery machines from Accuray with the intention to utilize these machines for OART.

Key Points: 
  • Thanks to funding from The Royal Marsden Cancer Charity, the center recently acquired two additional Radixact treatment delivery machines from Accuray with the intention to utilize these machines for OART.
  • ARTemis is a collaborative effort between RaySearch and Accuray, aiming to provide an online adaptive solution for clinicians using the RayStation treatment planning system with the Radixact Treatment Delivery System.
  • The Royal Marsden in Sutton plans to implement the full ARTemis package, which has also been funded by The Royal Marsden Cancer Charity.
  • Johan Löf, founder and CEO, RaySearch, says: "I am a strong believer of the clinical benefits of adaptive radiation therapy.

Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)

Retrieved on: 
Monday, November 20, 2023
Sale, Institute of Cancer Research, Translation, Research, AstraZeneca, Food, US Foods, PIK3CA, Mouse, Patient, PTEN, FDA, PKB, Marketing, Neoplasm, CRT, Therapy, US FDA, Drug discovery, AKT, Cancer, 3D, AKT1, Central nervous system, Recurrence, ICR, Pharmaceutical industry, Astex Pharmaceuticals

CAMBRIDGE, United Kingdom, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it is in line to receive a milestone payment from AstraZeneca on first commercial sale of the drug in the US and royalties from AstraZeneca on future sales following the US Food and Drug Administration’s (FDA) approval of Truqap™ plus Faslodex® as a treatment for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

Key Points: 
  • This is the third cancer drug in the last five years to reach market approval that has been discovered and developed under, or subsequent to, an Astex drug discovery collaboration.
  • Truqap was discovered by AstraZeneca following an earlier drug discovery research collaboration between Astex, The Institute of Cancer Research, London, and Cancer Research Technology (CRT; now Cancer Research Horizons) that was signed in 2003.
  • In 2010, AstraZeneca announced its discovery of Truqap, and began to develop the drug as a potential treatment for various forms of cancer.
  • This is also a great example of UK Biotech-Academia-Pharma collaboration and underlines the strength of the UK life sciences ecosystem.”
    Graphic of the hat-trick of three marketed cancer drugs discovered and developed under, or subsequent to, an Astex drug discovery collaboration with pharma

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NDA, Paclitaxel, Woman, Institute of Cancer Research, Research, Safety, Food, Avutometinib, Cancer, Letrozole, Disease, Verastem Oncology, Patient, Anastrozole, GOG, PFS, Consultant, RAMP, Breakthrough therapy, Part, FDA, NHS foundation trust, FRAME, ORR, The Institute, Ovarian cancer, FRCP, Doctor of Philosophy, Physician, Accelerated approval (FDA), Royal Marsden Hospital, Pharmaceutical industry, MBBS, Topotecan

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Part Two, Patient, Incidence, Institute of Cancer Research, Doctor of Philosophy, Poster, CD8, Phase, SITC, Immunotherapy, University of London, NK, The Institute, Cancer research, CET, University, Safety, Society, Therapy, Pharmaceutical industry, Vaccine, Cancer

Marseille, France, November 3, 2023, 7 pm CET – ImCheck Therapeutics presented today updated data from its ongoing Phase I/IIa EVICTION-2 clinical trial at the Society for Immunotherapy of Cancer 38th annual meeting in San Diego, USA.

Key Points: 
  • Marseille, France, November 3, 2023, 7 pm CET – ImCheck Therapeutics presented today updated data from its ongoing Phase I/IIa EVICTION-2 clinical trial at the Society for Immunotherapy of Cancer 38th annual meeting in San Diego, USA.
  • “The data show a clear increase in γ9δ2 T cell counts as well as activation and mobilization of CD8 T cells and NK cells, indicating ICT01 in combination with low dose IL-2 can generate a broad immune response.
  • EVICTION-2 is a two-part, open-label, Phase I/IIa trial assessing the safety, tolerability, pharmacodynamics and anti-tumor effects of ICT01 in combination with low dose IL-2 in advanced-stage solid tumor patients.
  • Reported treatment-related adverse events were mainly mild to moderate and correlated with the profile of ICT01 and IL-2 monotherapy.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023
Drug development, Survival, NHS foundation trust, Research, The Royal Marsden NHS Foundation Trust, Half-life, ESMO, Infrared spectroscopy correlation table, Institute of Cancer Research, DCR, Pharmacokinetics, Prostate cancer, CRUK, HER3, Clinical trial, Biology, Cancer, NRG1, The Institute, Interim, Cancer research, Pancreatic cancer, Oncology, Safety, European Society for Medical Oncology, The Christie NHS Foundation Trust, Royal Marsden Hospital, Cancer Research UK, Patient, Pharmaceutical industry, Phase

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023
Drug development, Survival, NHS foundation trust, Research, The Royal Marsden NHS Foundation Trust, Half-life, ESMO, Infrared spectroscopy correlation table, Institute of Cancer Research, DCR, Pharmacokinetics, Prostate cancer, CRUK, HER3, Clinical trial, Biology, Cancer, NRG1, The Institute, Interim, Cancer research, Pancreatic cancer, Oncology, Safety, European Society for Medical Oncology, The Christie NHS Foundation Trust, Royal Marsden Hospital, Cancer Research UK, Patient, Pharmaceutical industry, Phase

The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.

Key Points: 
  • The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
  • As of the data cut-off on 8 September 2023, the trial had enrolled 23 heavily pre-treated patients across various tumor types where HER3 may play an important role.
  • The dose escalation trial cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs) and there were no treatment discontinuations due to related adverse events.
  • " The Phase I/IIa clinical trial in the UK is sponsored and managed by Cancer Research UK's Centre for Drug Development.